(NASDAQ: RIGL) Rigel Pharmaceuticals's forecast annual revenue growth rate of -1.29% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Rigel Pharmaceuticals's revenue in 2025 is $267,921,000.On average, 2 Wall Street analysts forecast RIGL's revenue for 2025 to be $5,037,612,252, with the lowest RIGL revenue forecast at $4,991,782,349, and the highest RIGL revenue forecast at $5,083,442,156. On average, 4 Wall Street analysts forecast RIGL's revenue for 2026 to be $4,650,076,022, with the lowest RIGL revenue forecast at $3,975,093,917, and the highest RIGL revenue forecast at $6,213,494,576.
In 2027, RIGL is forecast to generate $4,621,842,648 in revenue, with the lowest revenue forecast at $4,495,456,151 and the highest revenue forecast at $4,808,462,734.